Navigation Links
Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
Date:10/25/2007

months; P = 0.05)

A scientific report of the safety and efficacy findings from this pivotal study was published earlier this year in the Journal of Clinical Oncology (25:1114, 2007).

Safety

Grade 3 or Grade 4 adverse events that occurred during treatment or within 30 days from last treatment in an increased percentage of patients in the Genasense group included, but were not limited to, thrombocytopenia, nausea, and intravenous-catheter complications. Adverse events resulted in discontinuation of therapy in an equal percentage of patients in both groups. Nine patients in the Genasense group and 5 patients in the chemotherapy-alone group had adverse events that resulted in death, including two patients in the Genasense group who died from complications associated with tumor lysis and infusion-related reactions.

About Chronic Lymphocytic Leukemia

CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding. More information about CLL can be accessed at the website for the Lymphoma Research Foundation at: http://www.lymphoma.org.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sonic Foundry completes $11.25M stock offer
2. Orion Energy completes $5M capital round
3. RedPrairie completes MARC acquisition
4. Metavante completes purchase of check processing firm
5. GE completes $1.2 billion acquisition
6. M & Is Metavante completes Brasfield Corp. acquisition
7. Metavante completes GHR Systems acquisition
8. Metavante completes TREEV acquisition
9. Johnson Controls completes sale of French unit
10. OpGen completes $5 million investment round
11. UW Hospital completes deployment of error-reducing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced ... - Global Strategic Business Report" report to their offering. ... Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The report ... , Europe , Asia-Pacific ... are provided for the period 2012 through 2020. Market data ...
(Date:8/19/2014)... 2014 In November 2012, the European Union ... Report (PBRER) in a new PSUR – responding to the ... profile of a drug. Adopted in many regions, the main ... Present a comprehensive and critical analysis of new or emerging ... Highlight any new evidence of the potential benefits of a ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... , , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.523 03/2002 , ... , , , , , ... , Cell type , Bacteria, ...
... , , , Multiporator , , , , , , ... Transfection Protocol , Protocol No. 4308 915.046 11/2001 , , ... , , Cell line , ... Transfection with , pActin-SV-EGFP, ...
... , , , , , , , Multiporator / Electroporator 2510 , ... , Transformation Protocol , Protocol ... , , , , , ... , , Cell type , ...
Cached Biology Technology:Mycobacterium avium 2L2 2Kluyveromyces lactis 2
(Date:8/20/2014)... YORK and POINT ROBERTS, Washington ... Biometrics Play a Key Role in Addressing Security Concerns in ... ), a global news source covering leading sectors including biometrics, ... wallet market. Jason Peaslee , Managing Partner ... Institute and Gino Pereira , CEO of NXT-ID, Inc. ...
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... this week,s Eos: Long-Term Ecological Research and Network-Level Science, ... how a wide range of ecosystems was responding to ... be particularly powerful if it coupled multiple decades of ... long-term experiments and models from dozens of different ecosystem ... is the Long-Term Ecological Research (LTER) Network, which will ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2
... at UC San Diego have developed a method that ... attach chemical probes onto proteins and subsequently remove them ... paper that appears online this week in the journal ... understand the biochemistry of naturally formed proteins in order ...
... to develop technologies to dramatically reduce the cost ... Institute (NHGRI), part of the National Institutes of ... DNA sequencing costs have fallen dramatically (see www.genome.gov/sequencingcosts), ... by genomics researchers. In 2004, NHGRI launched the ...
... Using ultrasound waves, MIT engineers have found a way ... transdermal drug delivery more efficient. This technology could pave ... according to the researchers. "This could be used ... example systemic drugs and proteins such as insulin, ...
Cached Biology News:Chemists develop reversible method of tagging proteins 2Chemists develop reversible method of tagging proteins 3New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs 2New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs 3Getting (drugs) under your skin 2Getting (drugs) under your skin 3
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Mouse monoclonal antibody to PAEP - progestagen-associated endometrial protein (placental protein 14, pregnancy-associated endometrial alpha-2-globulin, alpha uterine protein)...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
Biology Products: